Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MORBIUS

Financiado

Cure for Miniature Brittle Bones: Treatment of Osteogenesis ImpeRfecta patient-d...

Cure for Miniature Brittle Bones: Treatment of Osteogenesis ImpeRfecta patient-derived Bone organoids with Innovative AAV-mediated Ultimate Gene-editing System Osteogenesis Imperfecta (OI), also known as brittle bone disease, is a prevalent rare skeletal condition. With limited treatment options available and no known cure, individuals with OI endure numerous bone fractures throughout th... ver más

30/06/2027

FUNDACIÓN INSTITUT...

226K€

Presupuesto del proyecto: 226K€

Líder del proyecto

FUNDACIÓN INSTITUTO MEDITERRÁNEO PARA EL AVAN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 6M€

Ver 4 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-12

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100% 100%

4 Participantes

FUNDACIÓN INSTITUTO MEDITERR...

226.44K€ | Lider

ASML NETHERLANDS B.V.

N.D. | Participante

UNIVERSITY OF MASSACHUSETTS

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

UniMab Immune privileged immortal myogenic stem cells for gene th... 2M€ Cerrado

i-THYMUS The i-Thymus: wielding the potential of gene therapy, cell t... 4M€ Cerrado

NOVISTEM NOn-VIral gene modified STEM cell therapy 4M€ Cerrado

SAF2013-49147-P ESTRES REPLICATIVO DURANTE EL PROCESO DE REPROGRAMACION CELU... 182K€ Cerrado

SAF2017-88784-R DESARROLLO DE NUEVAS TECNOLOGIAS PARA LA EDICION PRECISA Y E... 136K€ Cerrado

SAF2014-59778-R DESARROLLO DE NUEVAS ESTRATEGIAS PARA EL TRATAMIENTO DE LA E... 169K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2024-05-12
Fecha Fin: 2027-06-30

Líder del proyecto

FUNDACIÓN INSTITUTO MEDITERRÁNEO PARA EL AVAN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 6M€

Presupuesto del proyecto 226K€

Descripción del proyecto Osteogenesis Imperfecta (OI), also known as brittle bone disease, is a prevalent rare skeletal condition. With limited treatment options available and no known cure, individuals with OI endure numerous bone fractures throughout their lives. To address the urgent need for an OI cure, MORBIUS aims to create a gene therapy: employ a cutting-edge AAV-mediated gene editing, to curatively repair the genetic defect in a model of patient bone tissue (‘mini brittle bone’). Within MORBIUS I will: 1) construct ‘mini brittle bones’ - an OI patient-derived induced stem cell-based bone organoid system, and 2) repair the genetic defect in the ‘mini brittle bones’ with the AAV-based CRISPR/Cas and GeneRide strategy. To this end, with access to one of the largest OI cell line biobanks in the world, I will combine highly innovative induced stem cell development techniques with the existing expertise in fabrication of bone organoids of the hosting team and genome modification competence of secondment host. Specifically, I will optimize a method of OI patient-derived induced mesenchymal stem cells embedding in a decellularized extracellular matrix to promote their natural differentiation and formation of ‘mini brittle bones’. Crafted ‘mini brittle bones’ will be transduced with bone-directed AAV vector carrying CRISPR/Cas and GeneRide systems to correct patient’s genetic defect by targeted insertion of a ‘donor’ sequence. In synergy with gene therapy research, during a non-academic placement with an OI patient organization, an interactive multilingual educational webapp on OI gene therapy and genetics will be developed. This will ensure early knowledge sharing, awareness, building of trust, and encouragement of OI individuals to actively engage in gene therapy advancements. MORBIUS outcomes will enhance the quality of life for individuals with OI and other rare bone disorders, but introduction of effective gene editing, bone organoid modeling, and knowledge sharing methods.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores